CTI BioPharma Corp. (NASDAQ:CTIC – Get Rating) has received an average recommendation of “Moderate Buy” from the seven brokerages that are presently covering the stock, Marketbeat.com reports. One analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that […]
CTI BioPharma Corp. (NASDAQ:CTIC – Get Rating) has received an average recommendation of “Moderate Buy” from the seven research firms that are covering the company, MarketBeat.com reports. One analyst has rated the stock with a hold recommendation and six have assigned a buy recommendation to the company. The average twelve-month price objective among brokerages that […]
CTI BioPharma Corp. (NASDAQ:CTIC – Get Rating)’s share price was up 4.4% on Monday . The company traded as high as $4.49 and last traded at $4.49. Approximately 869,000 shares changed hands during trading, a decline of 71% from the average daily volume of 3,020,629 shares. The stock had previously closed at $4.30. Wall Street […]
/PRNewswire/ CTI BioPharma Corp. (Nasdaq: CTIC), a commercial biopharmaceutical company focused on the development and commercialization of novel targeted.
Operator: Good morning, and welcome to the CTI BioPharma Fourth Quarter and Year-End 2022 Financial Results and Corporate Update Conference Call. As a reminder, this conference call is being recorded.